» Articles » PMID: 35715683

NMR-Based Metabolomics of Rat Hippocampus, Serum, and Urine in Two Models of Autism

Overview
Journal Mol Neurobiol
Date 2022 Jun 17
PMID 35715683
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorders (ASDs) are increasingly diagnosed as developmental disabilities of unclear etiology related to genetic, epigenetic, or environmental factors. The diagnosis of ASD in children is based on the recognition of typical behavioral symptoms, while no reliable biomarkers are available. Rats in whom ASD-like symptoms are due to maternal administration of the teratogenic drugs valproate or thalidomide on critical day 11 of pregnancy are widely used models in autism research. The present studies, aimed at detecting changes in the levels of hydrophilic and hydrophobic metabolites, were carried out on 1-month-old rats belonging to the abovementioned two ASD models and on a control group. Analysis of both hydrophilic and hydrophobic metabolite levels gives a broader view of possible mechanisms involved in the pathogenesis of autism. Hippocampal proton magnetic resonance (MRS) spectroscopy and ex vivo nuclear magnetic resonance (NMR) analysis of serum and urine samples were used. The results were analyzed using advanced statistical tests. Both the results of our present MRS studies of the hippocampus and of the NMR studies of body fluids in both ASD models, particularly from the THAL model, appeared to be consistent with previously published NMR results of hippocampal homogenates and data from the literature on autistic children. We detected symptoms of disturbances in neurotransmitter metabolism, energy deficit, and oxidative stress, as well as intestinal malfunction, which shed light on the pathogenesis of ASD and could be used for diagnostic purposes. These results confirm the usefulness of the noninvasive techniques used in ASD studies.

Citing Articles

The Metabolic Profile of Plasma During Epileptogenesis in a Rat Model of Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy.

Antmen F, Matpan E, Dayanc E, Savas E, Eken Y, Acar D Mol Neurobiol. 2025; .

PMID: 39904962 DOI: 10.1007/s12035-025-04719-6.

References
1.
Lai M, Lombardo M, Baron-Cohen S . Autism. Lancet. 2013; 383(9920):896-910. DOI: 10.1016/S0140-6736(13)61539-1. View

2.
Persico A, Bourgeron T . Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006; 29(7):349-358. DOI: 10.1016/j.tins.2006.05.010. View

3.
Kim Y, Leventhal B . Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biol Psychiatry. 2014; 77(1):66-74. PMC: 4260177. DOI: 10.1016/j.biopsych.2014.11.001. View

4.
Rubenstein J . Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder. Curr Opin Neurol. 2010; 23(2):118-23. DOI: 10.1097/WCO.0b013e328336eb13. View

5.
Fernandes D, Santos S, Coutinho E, Whitt J, Beltrao N, Rondao T . Disrupted AMPA Receptor Function upon Genetic- or Antibody-Mediated Loss of Autism-Associated CASPR2. Cereb Cortex. 2019; 29(12):4919-4931. PMC: 7963114. DOI: 10.1093/cercor/bhz032. View